CA2935857C - Radiolabeled tracers for poly (adp-ribose) polymerase-1 (parp-1), methods and uses therefor - Google Patents

Radiolabeled tracers for poly (adp-ribose) polymerase-1 (parp-1), methods and uses therefor Download PDF

Info

Publication number
CA2935857C
CA2935857C CA2935857A CA2935857A CA2935857C CA 2935857 C CA2935857 C CA 2935857C CA 2935857 A CA2935857 A CA 2935857A CA 2935857 A CA2935857 A CA 2935857A CA 2935857 C CA2935857 C CA 2935857C
Authority
CA
Canada
Prior art keywords
parp
compound
tumor
imaging
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2935857A
Other languages
English (en)
French (fr)
Other versions
CA2935857A1 (en
Inventor
Robert Mach
Wenhua Chu
Dong Zhou
Loren MICHEL
Delphine CHEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Washington University in St Louis WUSTL
Original Assignee
Washington University in St Louis WUSTL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Washington University in St Louis WUSTL filed Critical Washington University in St Louis WUSTL
Publication of CA2935857A1 publication Critical patent/CA2935857A1/en
Application granted granted Critical
Publication of CA2935857C publication Critical patent/CA2935857C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0468—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
    • A61B6/03—Computed tomography [CT]
    • A61B6/037—Emission tomography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Optics & Photonics (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Surgery (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Radiology & Medical Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA2935857A 2014-01-05 2015-01-05 Radiolabeled tracers for poly (adp-ribose) polymerase-1 (parp-1), methods and uses therefor Active CA2935857C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461923759P 2014-01-05 2014-01-05
US61/923,759 2014-01-05
PCT/US2015/010129 WO2015103526A1 (en) 2014-01-05 2015-01-05 Radiolabeled tracers for poly (adp-ribose) polymerase-1 (parp-1), methods and uses therefor

Publications (2)

Publication Number Publication Date
CA2935857A1 CA2935857A1 (en) 2015-07-09
CA2935857C true CA2935857C (en) 2020-12-15

Family

ID=53494075

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2935857A Active CA2935857C (en) 2014-01-05 2015-01-05 Radiolabeled tracers for poly (adp-ribose) polymerase-1 (parp-1), methods and uses therefor

Country Status (7)

Country Link
US (2) US9993570B2 (enExample)
EP (2) EP3424909A1 (enExample)
JP (2) JP6407303B2 (enExample)
CN (1) CN106458935B (enExample)
CA (1) CA2935857C (enExample)
ES (1) ES2700348T3 (enExample)
WO (1) WO2015103526A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3600314A1 (en) 2017-03-27 2020-02-05 Tesaro, Inc. Niraparib compositions
WO2018218025A1 (en) * 2017-05-24 2018-11-29 The Trustees Of The University Of Pennsylvania Radiolabeled and fluorescent parp inhibitors for imaging and radiotherapy
CA3076907A1 (en) * 2017-09-26 2019-04-04 Tesaro, Inc. Niraparib formulations
CN117180277A (zh) * 2023-08-04 2023-12-08 中国辐射防护研究院 一种核素标记的靶向探针及其制备方法和应用
CN117586270B (zh) * 2023-11-07 2025-09-23 北京脑重大疾病研究院 放射性2，7，9a-三氮杂苯并[cd]天青-6（7H）酮衍生物及其制备方法和应用
CN120247879A (zh) * 2024-01-02 2025-07-04 南京亘泰医药技术有限公司 一种parp1和ulk1双靶点抑制剂及其制备方法与应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2234318T3 (es) * 1998-11-03 2005-06-16 ABBOTT GMBH & CO. KG 2-fenil-benzimidazoles sustituidos, su preparacion y uso.
HRP20010573B1 (en) 1999-01-11 2006-04-30 Agouron Pharmaceuticals Tricyclic inhibitors of poly(adp-ribose) polymerases
ECSP003637A (es) * 1999-08-31 2002-03-25 Agouron Pharma Inhibidores triciclicos de poli (adp-ribosa) polimerasas
HU0301154D0 (en) * 2003-04-28 2003-07-28 Hideg Kalman Dr Pharmaceutical composition
GB0428012D0 (en) * 2004-12-22 2005-01-26 Hammersmith Imanet Ltd Radiolabelling methods
US8329686B2 (en) * 2006-08-29 2012-12-11 Washington University Isatin analogues and uses therefor
CA2974246C (en) 2006-09-01 2020-02-25 Senhwa Biosciences, Inc. Tricyclic heteroaryl compounds and their use as protein modulators
US8506927B2 (en) * 2011-01-05 2013-08-13 Washington University Pegylated fluorobenzamide analogues, their synthesis and use in diagnostic imaging
AU2013311826A1 (en) * 2012-09-05 2015-03-26 Bayer Cropscience Ag Use of substituted 2-amidobenzimidazoles, 2-amidobenzoxazoles and 2-amidobenzothiazoles or salts thereof as active substances against abiotic plant stress

Also Published As

Publication number Publication date
EP3089965A1 (en) 2016-11-09
EP3089965A4 (en) 2017-06-21
WO2015103526A1 (en) 2015-07-09
CN106458935B (zh) 2019-05-28
EP3089965B1 (en) 2018-08-29
ES2700348T3 (es) 2019-02-15
JP6407303B2 (ja) 2018-10-17
EP3424909A1 (en) 2019-01-09
US9993570B2 (en) 2018-06-12
JP2017505336A (ja) 2017-02-16
CN106458935A (zh) 2017-02-22
US20160339124A1 (en) 2016-11-24
CA2935857A1 (en) 2015-07-09
JP2019001820A (ja) 2019-01-10
US20180326100A1 (en) 2018-11-15

Similar Documents

Publication Publication Date Title
Zhou et al. Synthesis,[18F] radiolabeling, and evaluation of poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors for in vivo imaging of PARP-1 using positron emission tomography
CA2935857C (en) Radiolabeled tracers for poly (adp-ribose) polymerase-1 (parp-1), methods and uses therefor
JP7073270B2 (ja) 前立腺がんの内部放射線療法のための前立腺特異的膜抗原を標的とした高親和性薬剤
JP7622113B2 (ja) Ｐｓｍａ阻害剤を含有する１８ｆ標識トリアゾール
KR102531494B1 (ko) 탄산 탈수효소 ix를 표적으로 하는 핵 영상화 및 방사선치료 제제 및 이의 용도
JP2004525919A (ja) 上皮増殖因子受容体チロシンキナーゼの放射能標識された不可逆的阻害剤ならびに放射線画像化および放射線治療におけるその使用
Sneddon et al. Synthesis and in vivo biological evaluation of 68Ga-labeled carbonic anhydrase IX targeting small molecules for positron emission tomography
US9340532B2 (en) Methods and compositions for inhibiting CNKSR1
US7390902B2 (en) Sigma-2 receptor radiotracers for imaging the proliferative status of solid tumors
Tu et al. Synthesis and in vivo evaluation of [11C] PJ34, a potential radiotracer for imaging the role of PARP-1 in necrosis
JP6840666B2 (ja) 新規なアントラニル酸誘導体
Chen et al. Development of a highly-specific 18F-labeled irreversible positron emission tomography tracer for monoacylglycerol lipase mapping
JP2007505101A (ja) 放射性標識されたアニリノキナゾリン型化合物ならびに放射線画像化および放射線治療におけるその使用
Class et al. Patent application title: Radiolabeled Tracers for Poly (ADP-RIBOSE) Polymerase-1 (PARP-1), Methods and Uses Therefor
US20210163453A1 (en) Derivatives of papaverine that are effective hypoxic tumor radiosensitizers
HK1231057A1 (en) Radiolabeled tracers for poly (adp-ribose) polymerase-1 (parp-1), methods and uses therefor
HK1231057B (en) Radiolabeled tracers for poly (adp-ribose) polymerase-1 (parp-1), methods and uses therefor
US20170174632A1 (en) 4-oxo-1, 4-dihydroquinoline-3-carboxamide as selective ligand for cannabinoid receptor 2 for diagnosis and therapy
US10434195B2 (en) Methylsulfonamide derivatives and uses related thereto
Zeng et al. Development of Preladenant-Based Radiotracers for Imaging A2AR in Tumors
Lee et al. Synthesis and evaluation of 18F-labeled PPARγ antagonists
US20240174608A1 (en) Compounds for brain imaging
US8993634B2 (en) Methods and use of compounds that bind to Her2/neu receptor complex
US10912850B2 (en) 18F-FNDP for pet imaging of soluble epoxide hydrolase (sEH)

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20191230

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241227

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241227